SCHEMBL18163759

SCHEMBL18163759

CCOC(=O)/C=C/c1c(NS(=O)(=O)c2ccc[nH]2)cc2c(ncn2C)c1F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 5/20 0.38
AKT1 P31749 2/20 0.38
LMNA P02545 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ABCB11 O95342 1/20 0.32
NQO2 P16083 1/20 0.32
MAP2K2 P36507 1/20 0.32
MAP2K1 Q02750 1/20 0.32
P2RY12 Q9H244 1/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
XPO1 O14980 1/20 0.32
CYP3A4 P08684 1/20 0.32
TP53 P04637 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18148044 0.87 LMNA (0.37) CNKSR1AKT1LMNAMEN1KMT2A
SCHEMBL18148041 0.87 LMNA (0.37) CNKSR1AKT1LMNAMEN1KMT2A
SCHEMBL18160911 0.84 CNKSR1 (0.55) CNKSR1AKT1MEN1KMT2AALDH1A1
SCHEMBL18147963 0.82 PIK3CA (0.40) CNKSR1LMNAALDH1A1POLB
SCHEMBL18148199 0.77 ACLY (0.38) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL18148024 0.76 LMNA (0.35) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL18163737 0.72 CNKSR1 (0.45) CNKSR1AKT1MEN1KMT2AALDH1A1
SCHEMBL18148031 0.72 TSHR (0.35) LMNAKMT2AALDH1A1SMN1; SMN2CYP3A4
SCHEMBL18148073 0.69 LMNA (0.33) LMNAMEN1KMT2A
SCHEMBL18148026 0.67 CNKSR1 (0.56) CNKSR1AKT1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885LMNA 1703/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885AKT1 780/4885LMNA 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.